As of Mar 24
| +0.305 / +0.79%|
The 18 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 36.88, with a high estimate of 43.12 and a low estimate of 30.92. The median estimate represents a -5.39% decrease from the last price of 38.99.
The current consensus among 20 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.